Breaking Cataract Cornea Hyperopia LASIK Myopia Patient Education PRK Surgery Next-generation IOLs advance complex cataract care Ağustos 26, 2025
Breaking Cataract Patient Education Surgery Technology Alcon presenting at APACRS 2025 Ağustos 21, 2025
Breaking Clinical Trial Myopia Treatment OCT changes with low-level red light therapy for myopia in children Ağustos 26, 2025
Breaking Cataract Patient Education Recommendation Surgery Treatment Global Spotlight: The Most Cost-Effective Countries for Cataract Surgery Eylül 10, 2025
Home Patient Education A scoping review of artificial intelligence as a medical device for ophthalmic image analysis in Europe, Australia and America | npj Digital Medicine – Nature Share your love
A scoping review of artificial intelligence as a medical device for ophthalmic image analysis in Europe, Australia and America | npj Digital Medicine Nature Source: Author: | Date: 2025-05-29 07:00:00 Source: Author: | Date: 2025-05-29 07:00:00 Share your love Previous Yazı Flipped and traditional classrooms in ophthalmology: an evaluation of the impact of a crossover study - Nature Next Yazı Historic $40 Million Gift to CU Anschutz Department of Ophthalmology Will Fuel Research and New Therapies - CU Anschutz newsroom Related Posts FDA grants breakthrough therapy designation to Nacuity’s NPI-001 for retinitis pigmentosa | Ophthalmology TimesEkim 3, 2025 AAVantgarde’s AAVB-039 gene therapy to treat Stargardt disease receives orphan drug status from FDA | Ophthalmology TimesEkim 3, 2025 Q&A: The ARCHER trial and the importance of continued GA research | Ophthalmology TimesEkim 3, 2025 Leave a ReplyCancel ReplyE-posta adresiniz yayınlanmayacak. Gerekli alanlar * ile işaretlenmişlerdir Name * Email * Website Add Comment * Save my name, email and website in this browser for the next time I comment.Yorum gönder
FDA grants breakthrough therapy designation to Nacuity’s NPI-001 for retinitis pigmentosa | Ophthalmology TimesEkim 3, 2025
AAVantgarde’s AAVB-039 gene therapy to treat Stargardt disease receives orphan drug status from FDA | Ophthalmology TimesEkim 3, 2025
